Skip to main content

GOLDMAN SACHS GROUP INC

Position in DNLI — Denali Therapeutics Inc.

CIK 886982 NEW YORK, NY

Position in DNLI

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$84,619,295
+$21,290,190 QoQ
Shares Held
4,407,255
+14.9% QoQ
Ownership
2.78%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 92.50277099918203.ToString("F0")% Shared 0.574030774257446.ToString("F0")% None 6.9231982265605225.ToString("F0")%

Common Shares in DNLI Over Time

Shares Held

Position Value (USD)

Derivatives in DNLI

reported options exposure · as of Jun 30, 2021
CallValue
$0
CallShares
0
PutValue
$2,353,200
PutShares
30,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $10,293,152,367 across 364 Biotechnology names. DNLI ranks #29 (0.8% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in DNLI

Export CSV
26 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $84,619,295 4,407,255
2025-12-31 $63,329,105 3,835,803
2025-09-30 $31,416,995 2,163,705
2025-06-30 $26,095,882 1,865,324
2025-03-31 $22,731,899 1,672,078
2024-12-31 $21,552,318 1,057,523
2024-09-30 $39,844,624 1,367,821
2024-06-30 $28,303,437 1,218,925
2024-03-31 $18,557,487 904,361
2023-12-31 $8,451,054 393,805
2023-09-30 $8,404,516 407,393
2023-06-30 $19,031,411 644,914
2023-03-31 $13,198,301 572,843
2022-12-31 $21,454,078 771,452
2022-09-30 $22,350,667 728,272
2022-06-30 $12,382,436 420,742
2022-03-31 $13,068,353 406,228
2021-12-31 $18,320,074 410,764
2021-09-30 $53,303,350 1,056,558
2021-06-30 $46,108,443 587,818
2021-06-30 $2,353,200 30,000
2021-03-31 $36,992,291 647,851
2020-12-31 $58,832,521 702,394
2020-09-30 $18,113,569 505,542
2020-06-30 $5,508,420 227,809
2020-03-31 $2,300,201 131,365